Optimizing the sequence of anti-EGFR targeted therapy in EGFR-mutant lung cancer
Explore this paper's citation graph
Summary
It is found that AZD9291 was more potent than A+C at inhibiting cell growth and EGFR signaling in this setting, and provides a framework for future clinical trials testing different treatment sequences.
- Type
- article
- Published
- 2014-12-04
- Cited by
- 32
- References
- 53
- Access
- Open access
- OpenAlex
- https://openalex.org/W2078443595
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:1030690
Keywords
Lung cancer, Mutant, Targeted therapy, Cancer, Medicine
References
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
- Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1
- EGFR mutations in small-cell lung cancers in patients who have never smoked.
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
- Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
- Anticancer drugs: To the rescue?
- Glucocorticoid Receptor Confers Resistance to Anti-Androgens by Bypassing Androgen Receptor Blockade
- Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.
- Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
- AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
- Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
- Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
Cited by
- 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFR(L⁸⁵⁸R/T⁷⁹⁰M).
- Afatinib plus cetuximab delays resistance compared to single agent erlotinib or afatinib in mouse models of TKI-naïve EGFR L858R-induced lung adenocarcinoma
- ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma
- AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.
- Sequence of treatment in locally advanced and metastatic renal cell carcinoma
- Sequential Inhibitor Therapy in CML: In Vitro Simulation Elucidates the Pattern of Resistance Mutations after Second- and Third-Line Treatment
- Old habits die hard: Addiction of BRAF-mutant cancer cells to MAP kinase signaling
- The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
- A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
- EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer
- Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer—Letter
- AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells
- New data on clinical decisions in NSCLC patients with uncommon EGFR mutations
- Osimertinib – nová volba léčby pro pacienty s mutací EGFR T790M
- Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
- Liposomal curcumin and its application in cancer
- Gefitinib: an “orphan” drug for non-small cell lung cancer
- Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer
- Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
- Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
Related papers
- Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report
- Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib.
- The effect of erlotinib on EGFR and downstream signaling in oral cavity squamous cell carcinoma
- In Silico Identification of Novel Erlotinib Analogues Against Epidermal Growth Factor Receptor.
- Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)
- Blocking epidermal growth factor receptor signal pathway to inhibit cell growth of nasopharynx cancer
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
- Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
- Kinetic and thermodynamic insights into interaction of erlotinib with epidermal growth factor receptor: Surface plasmon resonance and molecular docking approaches.
- Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers